Saturday 7 November 2026
Export STLN’s income statement to Excel — free account
Starling Oncology, Inc.
STLN Healthcare Medical Care Facilities
Starling Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.7 million, up 27.8% from fiscal 2024.
- Revenue
- +24.3%
- EPS
- +7.14%
- Free cash flow
- +167.1%
- Total debt
- −4.82%
Quarter to September 2026, against a year earlier
3.51
3.19
−47.61%
Follow STLN
Alert me
| Sep '26 From the 10-Q filed 6 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 5 | 4 | 4 |
+8 more TTM periods Free account |
| 143.21% | 214.12% | 775.91% | 999.19% | ||
| (20.23%) | (21.47%) | (26.19%) | (35.93%) | ||
ROIC |
0.00% | (117.66%) | (63.75%) | (80.21%) | |
Return on Tangible Assets |
(144.55%) | (81.31%) | (90.26%) | (115.51%) | |
Average Days of Receivables |
35.77 | 41.46 | 39.76 | 43.07 | |
Free Cash Flow per Share |
0.18 | (0.03) | (0.25) | (0.30) | |
Free Cash Flow |
18.83 | (3.29) | (25.73) | (27.79) | |
Capital Expenditures |
(4.27) | (3.61) | (3.91) | (3.20) | |
| Other line items | |||||
Cash ROIC |
26.13% | (3.42%) | (27.78%) | (29.17%) | |
Accounts Receivable Turnover |
10.27 | 9.58 | 10.00 | 9.31 | |
Accounts Payable Turnover |
0.00 | 10.40 | 12.04 | 12.63 | |
Inventory Turnover |
0.00 | 27.66 | 25.32 | 31.68 | |
Average Days of Payables |
0.00 | 44.44 | 37.54 | 36.96 | |
Days of Inventory on Hand |
0.00 | 14.75 | 19.14 | 14.45 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
19.07% | 18.98% | 19.86% | 21.00% | |
Share Based Compensation of Revenue |
0.87% | 0.87% | 0.88% | 0.91% | |
Interest Coverage |
(2.79) | (3.42) | (4.28) | (3.20) | |
Operating CF/Net income |
(0.65) | (0.01) | 0.50 | 0.41 | |
Depreciation/Fixed assets |
0.00 | 1.10 | 1.07 | 1.43 | |
Capex/Depreciation |
0.00 | (0.31) | (0.34) | (0.21) | |
Revenue per Share |
5.92 | 5.70 | 5.36 | 5.44 | |
Operating CF per Share |
0.22 | 0.00 | (0.21) | (0.27) | |
Capex per Share |
(0.04) | (0.04) | (0.04) | (0.03) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 6 Nov 2026